Medtech

Vantage logo

Covid-19 divides the biggest medtechs

Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.

Company Events

Interviews

Vantage logo

Zynerba hopes to crack fragile X at last

The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.

Evaluate Vantage Homepage